News

Metformin Use Tied to Reduced Mortality in IPF, Diabetes

Treatment with metformin, a medication commonly used to lower blood sugar levels in people with diabetes, was associated with a significantly lower risk of death or hospitalization in patients with diabetes and idiopathic pulmonary fibrosis (IPF), according to a study based on insurance data. The study, “Evaluation for…

With Positive Early Findings, Phase 2 Cudetaxestat Trial Expected Soon

Blade Therapeutics’ experimental oral therapy, Cudetaxestat (BLD-0409), was found to significantly reduce lung scarring (fibrosis) and the levels of fibrotic markers and pro-fibrotic molecules in a mouse model of pulmonary fibrosis. “Cudetaxestat displayed direct anti-fibrotic effects on multiple biomarkers in a preclinical lung fibrosis model,” Blade said in…

BI 1015550 Slows IPF Lung Function Decline in Phase 2 Clinical Trial

Boehringer Ingelheim’s experimental oral therapy, BI 1015550, slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF), regardless of whether they were receiving approved anti-scarring therapies, according to final data from a Phase 2 clinical trial. “As the global market leader in pulmonary fibrosis, we have the ambition…

Ofev for PF-ILD Now Reimbursed in 7 regions of Canada

Ofev (nintedanib), a medicine approved to treat progressive fibrosing interstitial lung disease (PF-ILD), now is available for public reimbursement in Ontario, Quebec, New Brunswick, Newfoundland and Labrador, Alberta, and the Northwest Territories. The therapy also will be reimbursed through the Non-Insured Health Benefits (NIHB) program, which provides eligible First…

Organizations Rally to Help Ukrainian Rare Disease Patients

A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…

GALACTIC-1 Trial of Inhaled IPF Therapy Hits Enrollment Target

Less than 14 months after stopping its GALACTIC-1 study for certain patients due to safety concerns, Galecto has hit its enrollment target for the Phase 2b trial — now under a revised protocol — testing its investigational inhaled therapy GB0139 for idiopathic pulmonary fibrosis (IPF). Galecto had resumed trial…